



NeuroVista Hires Hugh H. Matsubayashi as Vice President of Intellectual Property

Seattle, WA—March 15, 2008— NeuroVista Corporation, a medical device company pioneering new technologies for the management and treatment of epilepsy, has hired Hugh H. Matsubayashi as Vice President of Intellectual Property. Mr. Matsubayashi will be responsible for significantly expanding NeuroVista’s in-house capabilities to develop its intellectual property portfolio. NeuroVista currently has more than 50 issued or pending patents.

Mr. Matsubayashi brings 10 years of experience practicing intellectual property law, including intellectual property counseling and strategic planning, patent prosecution and intellectual property support for litigation and corporate transactions. Previously, he was a partner at the intellectual property law firm of MacPherson Kwok Chen & Heid LLP in Silicon Valley. He developed and managed patent portfolios for clients in a wide range of technology areas, including medical devices, electro-mechanical devices, and computer hardware and software.

“Intellectual property is becoming an increasingly complex aspect of developing innovative medical technologies,” said John F. Harris, President and Chief Executive of NeuroVista. “Hugh will significantly enhance our ability to rapidly expand our extensive IP portfolio.”

Prior to joining MacPherson Kwok Chen & Heid LLP, Mr. Matsubayashi worked as a patent associate at the law firm Morrison & Foerster LLP and in-house as Senior Patent Counsel for Sun Microsystems, Inc. He has represented clients in a wide array of matters, including prosecution of domestic and international patent applications and performing intellectual property due diligence investigations for private investments and public offerings. Mr. Matsubayashi received a BS in mechanical engineering from the University of California at Berkeley and a JD from the University of Washington School of Law.

About NeuroVista

NeuroVista is a Seattle based medical device company pioneering new technologies for the management and treatment of epilepsy, a condition that affects approximately 1% of the population or roughly 2.5 million individuals in the United States. The company seeks to not only improve the quality of life for people with this debilitating condition, but also to become a leading innovator in the rapidly growing field of implantable neurotechnology. For more information, please visit www.neurovista.com.